Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results.
![](https://i.ytimg.com/vi/HPvSwg19WHs/maxresdefault.jpg)